XRAY leans on its Return-to-Growth plan, new distributor wins and AI-enabled launches ??? while forex and Europe demand softness linger.
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock?
DENTSPLY SIRONA stock slips after Q1 earnings miss estimates as margin pressure offsets revenue growth in key healthcare segments.
DENTSPLY SIRONA Inc. (XRAY) Q1 2026 Earnings Call Transcript
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dentsply International (XRAY) came out with quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.43 per share a year ago.
XRAY heads into Q1 earnings with U.S. softness, tariff pressure and transformation costs weighing on margins as investors watch for signs of stabilization.
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gregory Lucier acquired 15,000 shares for a total of approximately ~$187,000 on March 9, 2026. No direct holdings were involved in the transaction; all shares are held indirectly via trusts or similar entities.
Dentsply Sirona and Siemens Healthineers win FDA clearance for the first dental-dedicated MRI designed to improve soft-tissue dental imaging and diagnostics.
DENTSPLY SIRONA Inc. (XRAY) Presents at Leerink Global Healthcare Conference 2026 Transcript
Review Dentsply's (XRAY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.